Arctic Therapeutics key facts
- Operator of a drug discovery and development company intended to identify the genetic underpinnings of rare and common diseases.
- It has raised $27.4M; the latest was Later Stage VC ($27.4M) in Jan 2025.
- Notable investors include European Innovation Council, Nancy Lurie Marks Family Foundation, 21 Impact Labs, Kaldbakur, Sanos Group.
- Status: Privately Held (backing).
Who backs Arctic Therapeutics
5- ·Watch Arctic Therapeutics: the Monday email on marks, rounds and moves
Arctic Therapeutics funding rounds
No funding rounds for Arctic Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Arctic Therapeutics investors
5 investors are on record for Arctic Therapeutics, including European Innovation Council, Nancy Lurie Marks Family Foundation, 21 Impact Labs and Kaldbakur.
About Arctic Therapeutics
Operator of a drug discovery and development company intended to identify the genetic underpinnings of rare and common diseases. The company specializes in using bioinformatic approaches and AI to eliminate significant risks associated with traditional drug development, as well as sharply reducing the enormous cost, enabling healthcare operators to offer patients the ability to understand their genetic results and how these results guide individual therapies.
- Sector
- Healthcare
- HQ
- Reykjavik, Iceland
- Founded
- 2015
- Employees
- 21
- Website
- arctictherapeutics.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Arctic Therapeutics doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.